Member Connect

Log in

Login to your account

Password *
Remember Me
Wednesday, 16 December 2015 12:30

Paper 2015-12/1

Rate this item
(0 votes)
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study


Authors: Günther, G.; van Leth, F.; Altet, N.; Dedicoat, M.; Duarte, R.; Gualano, G.; Kunst, H.; Muylle, I.; Spinu, V.; Tiberi, S.; Viiklepp, P.; Lange, C.; for the TBNET

Source: The International Journal of Tuberculosis and Lung Disease, Volume 19, Number 12, 1 December 2015, pp. 1524-1527(4)

Publisher: International Union Against Tuberculosis and Lung Disease



The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).



Read 3871 times Last modified on Wednesday, 12 July 2017 18:00
More in this category: « Paper 2015-11/1